ended

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced the publicationof data from a pivotal Phase III clinical trial of ZYFLO CR(TM)(zileuton) extended-release tablets in the June 2007 issue of theJournal of Asthma. ZYFLO CR was approved by the U.S. Food and DrugAdministration (FDA) on May 30, 2007. Critical Therapeutics,together with it...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many asfirst-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the16th European Stroke Conference in Glasgow confirm that therapywith dipyridamole plus ASA (extended-release dipyridamole plus ASAis marketed as Aggrenox® or Asasantin® Retard) is superiorto ASA* alone in...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today the positive results of studies of theinvestigational medication guanfacine extended release (GXR,previously referred to as SPD503), a selectivealpha-2A-adrenoceptor agonist. These data from two short-term phaseIII placebo-controlled studies and two long-term phase IIIopen-label studies, presented at the 2007 Amer...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interactionwith paliperidone ER SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration ofpaliperidone extended-release (ER) tablets, blood levels of thedrug were not affected when given with a common antidepressant,according to new data presented today at the 160th Annual Meetingof the American Psychiatric Association. Paroxetine,...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR-- WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ --AstraZeneca today announced that two analyses from a large-scalestudy that investigated the efficacy of SEROQUEL XR(TM) (quetiapinefumarate) Extended-Release Tablets, a once-daily medicine for thetreatment of schizophrenia in adult patients, were presented todayat the annual meeti...

Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke

NICE Appraisal Committee concludes that alteplase is clinicallyand cost effective INGELHEIM/Germany, 14 May 2007 – A new clinical appraisalpublished by the National Institute for Health and ClinicalExcellence (NICE) in the UK has recommended the use of alteplasefor the treatment of patients with acute ischaemic stroke, based onits clinical and cost effectiveness...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ --Alpharma Inc. , a leading global specialty pharmaceutical companythrough its Pharmaceuticals Division, this week presented positiveresults of a pharmacokinetic study of its investigationalabuse-deterrent, extended-release opioid at the 26th annualscientific meeting of the American Pain Society in Washington, D.C.The data demonstrat...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

'Off' Time Reduced By an Average of More Than Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ --Adding the once daily, investigational medication REQUIP(R)(ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets toParkinson's patients' existing levodopa (L-dopa) therapysignificantly reduced 'off' time, allowing patients to continuetheir daily activities for a l...